Abstract
The story of hepatitis C virus (HCV) therapy is about to add one of its biggest chapters. From the serendipitous beginnings in the 1980s when investigators noted that interferon improves liver enzymes in non-A, non-B hepatitis, to the discovery and naming of the hepatitis virus, to the addition of ribavirin, to the pegylation of interferon, and now to the first direct-acting antivirals (DAA), the history of HCV is an intriguing one that continues to unfold. Along with the first DAAs, other important findings have helped explain long-observed differences between various ethnic groups, as well as new predictive information that can be gleaned from some of the observed adverse events.
Original language | English (US) |
---|---|
Pages (from-to) | 72-77 |
Number of pages | 6 |
Journal | Current Gastroenterology Reports |
Volume | 13 |
Issue number | 1 |
DOIs | |
State | Published - Feb 2011 |
Externally published | Yes |
Keywords
- Boceprevir
- Direct-acting antivirals
- Hepatitis C
- Pegylated interferon
- Polymerase inhibitors
- Protease inhibitors
- Ribavirin
- Telaprevir
ASJC Scopus subject areas
- Gastroenterology